Enhancement In Data Science To Drive The U.S Bacterial Conjunctivitis Drugs Market, Reaching USD 439.8 Mn

According to a new market report published by Persistence Market Research "The U.S Market Study on Bacterial Conjunctivitis Drugs: fluoroquinolones to be the Largest Segment by 2024" the bacterial conjunctivitis drugs market in the U.S. was valued at USD 473.3 million in 2013 and is estimated to reach a market worth of USD 439.8 million in 2024, at a CAGR of 2.7% from 2012 to 2018 and (-3.73%) from 2018 to 2024.

Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical). Bacterial conjunctivitis is one of the most commonly observed eye problems across all age groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata, Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.).

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/5192

As reported by Healio (specialty medical news and journal publisher), approximately 5 million acute bacterial conjunctivitis cases are reported in the U.S. each year. Thus, high prevalence of bacterial conjunctivitis in the country demands effective medications, thereby driving the growth of the bacterial conjunctivitis drugs market in the U.S.However, despite the increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in the U.S. is likely to witness negative growth due to the patent expirations of major blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few years.

Company Profiles:

Actavis plc.
Akorn, Inc.
Bayer AG.
F. Hoffmann-La Roche, Ltd.
Merck & Co., Inc.
Novartis AG.
Perrigo Company plc, Pfizer, Inc.
Santen Pharmaceutical Co., Ltd.
Valeant Pharmaceuticals International, Inc.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/5192

Rise in ophthalmic bacterial infections is increasing the demand for antibacterial drugs in the U.S. According to a clinical study conducted by the scientists Amir A. Azari and Neal P. Barney, published in the Journal of the American Medical Association (JAMA) in 2013, bacterial conjunctivitis accounts for over 50% of the conjunctivitis cases in the U.S. It also quoted that the incidence of bacterial conjunctivitis was estimated to be 135 in 10,000 in a single study.These statistics indicate that the U.S. is witnessing high incidence of bacterial conjunctivitis, hence leading to increased demand for bacterial conjunctivitis drugs in the country.

Fluoroquinolones, aminoglycosides, macrolides and other antibacterials such as bacitracin, doxycycline, and ceftriaxone collectively form the bacterial conjunctivitis market; among which fluoroquinolones dominate the bacterial conjunctivitis drugs market in the U.S. with a share of more than 70% in 2013.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/5192

Fluoroquinolones are more widely prescribed as compared to other antibiotic drug classes for the treatment of bacterial conjunctivitis across the U.S. due to their higher efficacy against antibiotic-resistant bacterial strains and broad spectrum activity. However, the segment is expected to witness a significant decline in sales in the near future -from a CAGR of 4.9% from 2012 to 2018 to a CAGR of (-8.1%) from 2018 to 2024. Burgeoning influx of generic antibacterials as well as upcoming patent expiries of leading branded formulations such as Vigamox, Zymaxid, Moxeza, and Besivance are a few major factors that would adversely affect the growth of the segment.

With the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the bacterial conjunctivitis drugs market in the U.S. Hence, the future market growth would be contingent on commercialization of novel drugs for new indications.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/u.s-bacterial-conjunctivitis-drugs-market.asp

However, it has been observed that although the incidence rate of bacterial conjunctivitis is moderate in the U.S., the risk of morbidity is less, due to which the novel product pipeline for bacterial conjunctivitis is weak/dry. At present, only a few novel compounds are under investigation in both preclinical and clinical settings for the treatment of bacterial conjunctivitis.

The U.S. bacterial conjunctivitis drugs market is segmented as follows:

U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class

Fluoroquinolones
Ciprofloxacin
Ofloxacin
Levofloxacin
Moxifloxacin
Gatifloxacin
Besifloxacin
Aminoglycosides
Tobramycin
Gentamycin
Macrolides
Erythromycin
Azithromycin
Others

U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment

Vancomycin Ophthalmic Ointment
Early Stage (Phase I and Phase II trials) - Tabular Representation

Related Reports:

Dysphagia Diet Thickening Agents Market - https://www.persistencemarketresearch.com/market-research/dysphagia-diet-thickening-agents-market.asp

Acne Treatment Market - https://www.persistencemarketresearch.com/market-research/acne-treatment-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.